|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
BEFREE |
The purpose of this review was to investigate the effects of SGLT2 inhibitors across the spectrum of arterial hypertension.
|
31541572 |
2020 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
BEFREE |
We tested the hypothesis that SGLT2 inhibition with canagliflozin (CANA) prevents intrarenal AGT augmentation and ameliorates kidney injury and hypertension in T2DM.
|
30921791 |
2019 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
BEFREE |
Preventative cardiology data included the use of sodium glucose cotransporter-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin), proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors (alirocumab) and approaches of hypertension management.
|
31065993 |
2019 |
|
Hypertensive disease
|
0.300 |
AlteredExpression
|
group |
BEFREE |
Our results demonstrate that Hnrnpf plays a role in the development of hypertension and glycosuria through modulation of renal Agt and Sglt2 expression in mice, respectively.
|
31673025 |
2019 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
BEFREE |
Treatment of hypertension and sodium-glucose cotransporter-2 are able to improve arterial stiffness.
|
30113526 |
2019 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
BEFREE |
The present study was undertaken to investigate whether nondiabetic salt-sensitive hypertension and accompanying renal inflammation are ameliorated by SGLT2 inhibition.
|
31537914 |
2019 |
|
Hypertensive disease
|
0.300 |
GeneticVariation
|
group |
BEFREE |
SGLT2 inhibitors were associated with a lower risk of serious adverse events (RR 0.90, 95% CI 0.86 to 0.94, <i>P</i> < 0.001), death (RR 0.78, 95% CI 0.64 to 0.94, <i>P</i> < 0.05), gastroenteritis (RR 0.38, 95% CI 0.20 to 0.72, <i>P</i> < 0.05), arthralgia (RR 0.72, 95% CI 0.54 to 0.96, <i>P</i> < 0.05), hypertension (RR 0.61, 95% CI 0.50 to 0.75, <i>P</i> < 0.001), and edema/peripheral edema (RR 0.49, 95% CI 0.33 to 0.72, <i>P</i> < 0.001) compared to placebo.
|
31616297 |
2019 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
BEFREE |
SGLT2 Inhibitors and Mechanisms of Hypertension.
|
29349558 |
2018 |
|
Hypertensive disease
|
0.300 |
AlteredExpression
|
group |
BEFREE |
We have begun to characterize the effects of SGLT2 inhibitor on BP and sympathetic nervous activity (SNA) in salt-treated obese and metabolic syndrome rats, who develop hypertension with an abnormal circadian rhythm of BP, a non-dipper type of hypertension, and do not exhibit a circadian rhythm of SNA.
|
30093883 |
2018 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
BEFREE |
Recently developed drugs, such as GLP-1 receptor agonists, DPP-4 inhibitors and SGLT2 inhibitors, also have hypotensive actions, making them ideal for use in diabetics with hypertension.
|
29402981 |
2018 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
BEFREE |
Furthermore, SGLT-2 inhibitors showed greater reductions in body weight (SMD -0.72; 95% CI: -0.81, -0.63; p=0.000) from baseline, with an increased incidence of genital infections (OR 4.49; 95% CI: 2.96, 6.83; p=0.000) and pollakiuria (OR 2.24; 95% CI: 1.05, 4.79; p=0.037) and a decreased incidence of hypertension and hyperglycemia.
|
30261527 |
2018 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
BEFREE |
The SGLT2 inhibitor and ARB Combination theRapy in pAtients with diabetes and uncontrolled nocturnal hypertension (SACRA) study investigated changes in blood pressure (BP) with empagliflozin plus existing antihypertensive therapy.
|
30586745 |
2018 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
BEFREE |
Along with a mild antihyperglycemic effect, SGLT-2 inhibitors seem to possess multi-dimensional properties, affecting positively several recognized cardiovascular risk factors such as increased blood pressure, arterial stiffness, body weight and dyslipidemia.
|
28120716 |
2017 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
BEFREE |
Thus, SGLT2 inhibitors could potentially provide clinicians with a treatment option that addresses multiple pathophysiologic aspects of the cardiometabolic disease processes that may affect end-organ function in African-American patients with T2D and hypertension.
|
28351176 |
2017 |
|
Hypertensive disease
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Because these favorable effects presumably occur independent of blood glucose lowering, we also explore the potential use of SGLT2 inhibition in patients without T2D with HF or at risk of HF, such as in patients with coronary artery disease or hypertension.
|
29061576 |
2017 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
BEFREE |
Sodium-glucose co-transporters 2 (SGLT-2) inhibitors have emerged as a novel antidiabetic class of drugs that exert favourable results in a variety of other cardiovascular risk factors too, such as increased blood pressure and body weight.
|
27895093 |
2017 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
BEFREE |
To examine this further we administered the SGLT2 inhibitor, dapagliflozin, to 5/6 (subtotally) nephrectomised rats, a model of progressive chronic kidney disease (CKD) that like CKD in humans is characterised by single nephron hyperfiltration and intraglomerular hypertension and where angiotensin converting enzyme inhibitors and angiotensin receptor blockers are demonstrably beneficial.
|
26741142 |
2016 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
RGD |
We suggest that in renovascular hypertension, angiotensin II induced SGLT2 via the AT1 receptor, which was evidenced at both the functional and expression levels, probably contributing to increased absorption of Na+ and thereby to the development or maintenance of hypertension.
|
14506074 |
2004 |